23 Jul, 2026
According to Straits Research the global veterinary oncology market was valued at $1.35 billion in 2025 and is anticipated to grow from $1.49 billion in 2026 to $3.34 billion by 2034, registering a CAGR of 10.6% during the forecast period 2026–2034. on account of increasing regulatory approvals for veterinary oncology products. For instance, in 2018, Aratana Therapeutics obtained provisional clearance for its canine osteosarcoma vaccine from the U.S. Department of Agriculture’s Center for Veterinary Biologics.
The manufacturers are focused on undertaking acquisition strategies to expand their product portfolio and gain a competitive edge. For instance, in 2018, Zoetis acquired Abaxis, a firm focused on the growth, manufacturing, and distribution of diagnostic instruments for point-of-care veterinary services. Technological advancements in animal cancer treatment provide an impetus to the market growth. In 2018, AdvaVet, a subsidiary of Oasmia Pharmaceutical AB, developed an innovative technology, XR17, for formulating nanoparticles that make water-soluble to a single API or multiple APIs. This system increases solubility and guarantees safe animal administration of APIs.
The veterinary oncology market is driven by the increasing prevalence of cancer in companion animals and the growing demand for advanced veterinary healthcare services. Rising pet ownership, higher spending on animal health, and increasing awareness among pet owners regarding early cancer diagnosis and treatment are contributing to the adoption of veterinary oncology therapies. Additionally, the growing number of regulatory approvals for veterinary oncology products is accelerating the availability of innovative treatment options.
The market is also benefiting from strategic acquisitions, partnerships, and product portfolio expansions by leading animal health companies to strengthen their market presence. Investments in research and development have resulted in the introduction of advanced diagnostic technologies, targeted therapies, immunotherapies, and innovative drug delivery systems that improve treatment outcomes and enhance the safety of cancer therapies for animals.
Furthermore, continuous technological advancements in veterinary oncology, including nanoparticle-based drug formulations and precision treatment approaches, are creating new opportunities for market growth. Increasing focus on improving cancer care for companion animals, coupled with expanding veterinary healthcare infrastructure and ongoing innovation in oncology therapeutics, is expected to support the long-term growth of the veterinary oncology market.
By Therapy
By Animal Type
By Cancer Type
By Region
sales@straitsresearch.com